|
Acute monocytic leukemia
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Mutant CEBPA directly drives the expression of the targetable tumor-promoting factor CD73 in AML.
|
31309149 |
2019 |
|
Acute monocytic leukemia
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Additionally, overexpression of miR-155 was found to be significantly related to FLT3/ITD presence (OR=4.751, 95%CI [3.229-6.990], P<0.001), more WT1 mutation (OR=2.090, 95%CI [1.240-3.522], P=0.006) and less CEBPA mutation (OR=0.477, 95%CI [0.286-0.794], P=0.004) in 552 AML patients.
|
30719163 |
2019 |
|
Acute monocytic leukemia
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Companion gene mutations and their clinical significance in AML with double mutant CEBPA.
|
31477806 |
2019 |
|
Acute monocytic leukemia
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
The aim of this study was to explore the clinical features and prognostic significance of CSF3R mutations in AML patients with CEBPA double mutations (CEBPA<sup>dm</sup>).
|
31041512 |
2019 |
|
Acute monocytic leukemia
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
As a result, high TET1 expression was more common in M0/M1 morphology and genes of NPM1 mutations, and underrepresented in CEBPA double allele mutations in our AML patients.
|
29402726 |
2018 |
|
Acute monocytic leukemia
|
0.400 |
Biomarker
|
disease |
BEFREE |
LSD1 inhibition exerts its antileukemic effect by recommissioning PU.1- and C/EBPα-dependent enhancers in AML.
|
29453291 |
2018 |
|
Acute monocytic leukemia
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
As a result, high HIP1 expression was seen more frequently in older patients, M4/M5 morphology and genes of NPM1 and DNMT3A mutations, and underrepresented in favorable karyotype subgroups and CEBPA double allele mutations in our AML patients.
|
28452374 |
2017 |
|
Acute monocytic leukemia
|
0.400 |
Biomarker
|
disease |
GENOMICS_ENGLAND |
Germline Genetic Predisposition to Hematologic Malignancy.
|
28297620 |
2017 |
|
Acute monocytic leukemia
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
NPM1, FLT3 and CEBPA mutations in pediatric patients with AML from Argentina: incidence and prognostic value.
|
27436336 |
2016 |
|
Acute monocytic leukemia
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Chemo-genomic interrogation of CEBPA mutated AML reveals recurrent CSF3R mutations and subgroup sensitivity to JAK inhibitors.
|
27034432 |
2016 |
|
Acute monocytic leukemia
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Disease evolution and outcomes in familial AML with germline CEBPA mutations.
|
26162409 |
2015 |
|
Acute monocytic leukemia
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
We here analyze the frequency and types of CEBPA mutations and polymorphisms in a de novo AML patients from South India and tried to find out associations of these variations with different clinical parameters and the prognostic significance in AML.
|
25987038 |
2015 |
|
Acute monocytic leukemia
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
+8sole patients were older (p=0.013), presented lower WBC counts (p=0.010), harbored more often ASXL1 mutations (p<0.001) and RUNX1 mutations (p=0.009), but less frequent FLT3-ITD (p=0.038), NPM1 mutations (p<0.001) and double-mutated CEBPA (p=0.038) than NK patients.
|
25592059 |
2015 |
|
Acute monocytic leukemia
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
We report here the incidence of 12.6% of CEBPA mutants in the population of 262 normal karyotype AML (NK-AML) patients.
|
26460249 |
2015 |
|
Acute monocytic leukemia
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
The aim of this study was to analyze the long-term survival of AML patients with CEBPA mutations.
|
25214041 |
2014 |
|
Acute monocytic leukemia
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Moreover, low DAPK2 expression is also associated with C/EBPα-mutated AML patients, and we found C/EBPα-dependent regulation of DAPK2 during APL differentiation.
|
24038216 |
2014 |
|
Acute monocytic leukemia
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
The role of different genetic subtypes of CEBPA mutated AML.
|
24056881 |
2014 |
|
Acute monocytic leukemia
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Here we examined the CEBPA mutation status and clinical outcomes of pediatric AML patients treated in the AML-05 study.
|
25014773 |
2014 |
|
Acute monocytic leukemia
|
0.400 |
Biomarker
|
disease |
BEFREE |
C/EBPα and MYB regulate FLT3 expression in AML.
|
23340802 |
2013 |
|
Acute monocytic leukemia
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
CEBPA mutations were found in 11 (20%) of 55 AML patients.
|
22990006 |
2013 |
|
Acute monocytic leukemia
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Potent graft-versus-leukemia effect after reduced-intensity allogeneic SCT for intermediate-risk AML with FLT3-ITD or wild-type NPM1 and CEBPA without FLT3-ITD.
|
22766221 |
2012 |
|
Acute monocytic leukemia
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Multilineage dysplasia does not influence prognosis in CEBPA-mutated AML, supporting the WHO proposal to classify these patients as a unique entity.
|
22442349 |
2012 |
|
Acute monocytic leukemia
|
0.400 |
Biomarker
|
disease |
BEFREE |
A 25-probe set prediction signature for CEBPA(dm) AML showed 100% sensitivity and specificity.
|
21177436 |
2011 |
|
Acute monocytic leukemia
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Protein disulfide isomerase blocks CEBPA translation and is up-regulated during the unfolded protein response in AML.
|
21471526 |
2011 |
|
Acute monocytic leukemia
|
0.400 |
Biomarker
|
disease |
BEFREE |
Deficient CEBPA DNA binding function in normal karyotype AML patients is associated with favorable prognosis.
|
21389317 |
2011 |